Evidence map›Paper›PMID 42121261›Full record

ArticleBiomarker research2026

Tissue- and tumor-type-specific expression of internal-promoter-driven YEATS-domain-devoid isoforms of MLLT1 and MLLT3.

Sandra Dailhau, Ahmed Zamani, Romain Pfeifer, Chloé Bessière, Thérèse Commes, Olivera Casar-Borota, Christian Touriol, Fabienne Meggetto, Marina Bousquet, Nicolas Gilbert and 1 more

Abstract readLetter
In one paragraph

Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sandra DailhauUniv Toulouse, CNRS, INSERM, CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN), Toulouse, 31037, France.
Ahmed ZamaniUniv Toulouse, CNRS, INSERM, CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN), Toulouse, 31037, France.
Romain PfeiferUniv Toulouse, CNRS, INSERM, CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN), Toulouse, 31037, France.
Chloé BessièreUniv Toulouse, CNRS, INSERM, CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN), Toulouse, 31037, France.ORCID http://orcid.org/0000-0001-7518-3559
Thérèse CommesIRMB, Université de Montpellier, INSERM, Montpellier, France.ORCID http://orcid.org/0000-0002-7918-0176
Olivera Casar-BorotaDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0001-7376-7331
Christian TouriolUniv Toulouse, CNRS, INSERM, CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN), Toulouse, 31037, France.
Fabienne MeggettoUniv Toulouse, CNRS, INSERM, CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN), Toulouse, 31037, France.
Marina BousquetUniv Toulouse, CNRS, INSERM, CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN), Toulouse, 31037, France.ORCID http://orcid.org/0000-0001-8333-1144
Nicolas GilbertIRMB, Université de Montpellier, INSERM, Montpellier, France. nicolas.gilbert@inserm.fr.ORCID http://orcid.org/0000-0003-3311-7494
Stéphane PyronnetUniv Toulouse, CNRS, INSERM, CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Laboratoire d'Excellence Toulouse Cancer (Labex TOUCAN), Toulouse, 31037, France. stephane.pyronnet@inserm.fr.ORCID http://orcid.org/0000-0002-9562-5112

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As integral parts of the transcription super elongation complex, the ENL and AF9 proteins are two master regulators of gene expression involved in the development and homeostasis of various tissues. They are encoded by MLLT1 and MLLT3, two genes that frequently undergo oncogenic mutations or chromosomal translocations in cancers. In addition, we discovered an internal promoter driving the production of a YEATS (named after the five proteins first shown to contain this domain: Yaf9, ENL, AF9, Taf14, and Sas5)-domain-devoid AF9 isoform massively expressed in healthy hematopoietic stem cells (HSCs), as well as in the blasts of patients with extremely poor-prognosis acute myeloid leukemia (AML). Here, we show that such internal promoter is also active in a subset of digestive tissues, including the small intestine, colon and stomach. We also reveal the existence of a similar internal promoter in the MLLT1 locus that is inactive in the hematopoietic lineage and AML but functional in other healthy tissues, including the pituitary gland, brain, thyroid, uterus and lung. Furthermore, the YEATS-domain-devoid MLLT1 isoform may exhibit tumor-type-specific biomarker values, whereas full-length MLLT1 does not. It is highly expressed in the gonadotroph subtype of pituitary tumors, and its expression in non-small cell lung cancer inversely correlates with the epidermal growth factor mutation and a transcriptomic signature associated with a good prognosis. Thus, both MLLT1 and MLLT3 have tissue- and tumor-type-specific internal promoters driving expression of similar YEATS domain-devoid isoforms. This suggests that the functions of both MLLT1 and MLLT3 in tissue homeostasis and cancers, as well as their potentials as biomarkers should be re-evaluated taking into account expression of these YEATS-domain-devoid ENL and AF9 transcription factors.

Indexed as

Acute myeloid leukemiaAF9ENLHematopoiesisMLLT1MLLT3Non-small cell lung cancerPituitary tumor

Identifiers

PMID42121261
PMCPMC13169612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.